Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The Company’s first product is ColdZyme®, a mouth spray which can prevent and reduce the duration of the common cold, alleviate common cold symptoms and improve quality of life. ColdZyme is also effective for throat problems associated with colds. The product has been launched in about fifteen markets.
The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners.
In 2019 we took a strategic decision to broaden the use of our enzyme technology in order to better leverage its commercial potential. We have chosen three models for sales of our products: Mouth spray as a medical device, mouth spray as a cosmetic product and an enzyme formulation that is included in our customers' skin care products.
In 2019 Enzymatica entered into an agreement with its German partner STADA for sales of a new mouth spray for the German market, and in addition, signed an agreement with the German company Maren Cosmetics to deliver an enzyme formulation to their skin care products. Moreover, ABEX Pharmaceutica (PTY) LTD started to sell ColdGuard® (ColdZyme) in the South African market during spring of 2019. In early 2020, Enzymatica entered into an agreement with Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd., a subsidiary of China’s second largest pharmaceutical company, Shanghai Pharma, for marketing and sales of the mouth spray ColdZyme in China, with expected launch in 2022.